Cargando…
Letter to the Editor Regarding a Multicentric Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Healthcare
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684857/ https://www.ncbi.nlm.nih.gov/pubmed/36414884 http://dx.doi.org/10.1007/s40121-022-00728-3 |
| _version_ | 1784835380373094400 |
|---|---|
| author | Ito, Shun Banno, Masahiro Okazaki, Yuji |
| author_facet | Ito, Shun Banno, Masahiro Okazaki, Yuji |
| author_sort | Ito, Shun |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9684857 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Springer Healthcare |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96848572022-11-28 Letter to the Editor Regarding a Multicentric Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia Ito, Shun Banno, Masahiro Okazaki, Yuji Infect Dis Ther Letter Springer Healthcare 2022-11-22 2023-01 /pmc/articles/PMC9684857/ /pubmed/36414884 http://dx.doi.org/10.1007/s40121-022-00728-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
| spellingShingle | Letter Ito, Shun Banno, Masahiro Okazaki, Yuji Letter to the Editor Regarding a Multicentric Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia |
| title | Letter to the Editor Regarding a Multicentric Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia |
| title_full | Letter to the Editor Regarding a Multicentric Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia |
| title_fullStr | Letter to the Editor Regarding a Multicentric Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia |
| title_full_unstemmed | Letter to the Editor Regarding a Multicentric Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia |
| title_short | Letter to the Editor Regarding a Multicentric Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia |
| title_sort | letter to the editor regarding a multicentric phase 2 randomized controlled study on the efficacy and safety of reparixin in the treatment of hospitalized patients with covid-19 pneumonia |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684857/ https://www.ncbi.nlm.nih.gov/pubmed/36414884 http://dx.doi.org/10.1007/s40121-022-00728-3 |
| work_keys_str_mv | AT itoshun lettertotheeditorregardingamulticentricphase2randomizedcontrolledstudyontheefficacyandsafetyofreparixininthetreatmentofhospitalizedpatientswithcovid19pneumonia AT bannomasahiro lettertotheeditorregardingamulticentricphase2randomizedcontrolledstudyontheefficacyandsafetyofreparixininthetreatmentofhospitalizedpatientswithcovid19pneumonia AT okazakiyuji lettertotheeditorregardingamulticentricphase2randomizedcontrolledstudyontheefficacyandsafetyofreparixininthetreatmentofhospitalizedpatientswithcovid19pneumonia |